Balyasny Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Balyasny Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.8M	Sell	139,200 -55,600	-29%	-$6.94M	0.02%	739
2025 Q4	$23.8M	Sell	194,800 -61,200	-24%	-$7.02M	0.03%	629
2025 Q3	$25.7M	Buy	256,000 +141,000	+123%	+$12.7M	0.03%	605
2025 Q2	$9.54M	Sell	115,000 -107,600	-48%	-$8.58M	0.01%	988
2025 Q1	$18.1M	Buy	222,600 +64,800	+41%	+$5.79M	0.03%	644
2024 Q4	$14.2M	Sell	157,800 -900	-0.6%	-$87.2K	0.02%	808
2024 Q3	$15.7M	Buy	158,700 +42,100	+36%	+$4.14M	0.03%	742
2024 Q2	$10.8M	Buy	116,600 +104,600	+872%	+$9.38M	0.02%	851
2024 Q1	$1.14M	Sell	12,000 -28,600	-70%	-$2.65M	﹤0.01%	1731
2023 Q4	$3.63M	Buy	40,600 +27,300	+205%	+$2.03M	0.01%	1246
2023 Q3	$971K	Buy	+13,300	New	+$1.06M	﹤0.01%	1573
2023 Q1	–	Sell	-102,500	Closed	-$8.51M	–	3219
2022 Q4	$8.51M	Sell	102,500 -262,500	-72%	-$21.3M	0.02%	802
2022 Q3	$29M	Buy	365,000 +65,000	+22%	+$5.48M	0.09%	298
2022 Q2	$22.3M	Buy	300,000 +180,000	+150%	+$13.5M	0.07%	383
2022 Q1	$10.8M	Buy	120,000 +40,000	+50%	+$3.69M	0.03%	668
2021 Q4	$8.96M	Sell	80,000 -116,800	-59%	-$14.1M	0.03%	667
2021 Q3	$24.7M	Buy	+196,800	New	+$25.3M	0.1%	271
2020 Q3	–	Sell	-300,000	Closed	-$33.6M	–	1643
2020 Q2	$33.6M	Buy	+300,000	New	+$29.5M	0.29%	77

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Balyasny Asset Management's XBI Position: Q1 2026 in Review

Balyasny Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 53,091 shares — an estimated $6.63M sold.

Balyasny Asset Management first reported a position in XBI in Q2 2015 and held it in 19 quarters. The position peaked at $57.2M in Q3 2019. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Balyasny Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Balyasny Asset Management sold 53,091 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $6.63M.
Balyasny Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and held it in 19 quarters.
Balyasny Asset Management's State Street SPDR S&P Biotech ETF position peaked at $57.2M in Q3 2019.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.